Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for Budoprutug (CD19 Antibody) in Autoimmune Diseases. The expected timing is based on the latest available company guidance and may change.
08/06/26:- SC budoprutug multiple-dose autoimmune study planned; initial data expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.